Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioPharma CreditLSE:BPCR +1.45%51 Equity-to-Asset is 0.99 as of Dec. 2025, which is at its 10-year median of 0.99. GuruFocus rates LSE:BPCR with a GF Score™ of 51/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,630 Asset Management companies, BioPharma Credit ranks better than 90.8% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioPharma Credit's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $1,150.9 Mil. BioPharma Credit's Total Assets for the quarter that ended in Dec. 2025 was $1,168.4 Mil.
Therefore, BioPharma Credit's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.99.
The historical rank and industry rank for BioPharma Credit's Equity-to-Asset or its related term are showing as below:
LSE:BPCR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.98 Med: 0.99 Max: 1
Current: 0.99
During the past 9 years, the highest Equity to Asset Ratio of BioPharma Credit was 1.00. The lowest was 0.98. And the median was 0.99.
LSE:BPCR's Equity-to-Asset is ranked better than 90.8% of 1630
companies
in the Asset Management industry
Industry Median: 0.83
vs LSE:BPCR: 0.99
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioPharma Credit Equity-to-Asset Related Terms
BioPharma Credit Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BPCR vs BLK, BX, KKR: Equity-to-Asset Comparison
For the Asset Management subindustry, BioPharma Credit's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit Equity-to-Asset vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioPharma Credit's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a Equity-to-Asset of 0.99 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioPharma Credit and its competitors. This is near median its historical median of 0.99. Over the past decade, BioPharma Credit's Equity-to-Asset has ranged from 0.98 to 1.00. According to the industry distribution chart, BioPharma Credit ranks #150 out of 1630 companies in the Asset Management industry, placing it in the top 9.2%.
Is BioPharma Credit's Equity-to-Asset too high?
BioPharma Credit's current Equity-to-Asset of 0.99 is near median its 10-year median of 0.99. Over the past 10 years, this metric has ranged from a low of 0.98 to a high of 1.00. The Asset Management industry median Equity-to-Asset is 0.83. BioPharma Credit's value of 0.99 is 19.3% above this industry median. Based on the distribution chart, BioPharma Credit ranks #150 out of 1630 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, BioPharma Credit has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Equity-to-Asset compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #150 out of 1630 companies for Equity-to-Asset. This places BioPharma Credit in the top 9% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.83. BioPharma Credit's value of 0.99 is 19.3% above this benchmark. Historically, BioPharma Credit's own Equity-to-Asset has ranged from 0.98 to 1.00 over the past decade. While the company's 10-year median is 0.99 vs. the industry median of 0.83, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Asset Management company?
The median Equity-to-Asset among Asset Management companies is 0.83, based on 1,630 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current Equity-to-Asset of 0.99 is 19.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median Equity-to-Asset is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current Equity-to-Asset is 0.99, which is near median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.98 — trading 2.3% above its estimated fair value. The current Equity-to-Asset is 0.99, which is near median its 10-year median of 0.99 and 19.3% above the Asset Management industry median of 0.83. BioPharma Credit's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Equity-to-Asset is 0.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued.
The current stock price of $0.98 is trading 2.3% above its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
Equity-to-Asset: 0.99 (near median its 10-year median of 0.99)
GF Value™: $0.96 vs. price of $0.98 (2.3% above fair value)
Industry Position: 19.3% above the Asset Management median (#150 of 1630)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
51GF Score
Get the complete analysis for LSE:BPCR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
